Abstract
hMATE1 (human multidrug and toxin compound extrusion-1; encoded by SLC47A1) is thought to have an important function in the renal and hepatic elimination of drugs, endogenous compounds and environmental toxins. The goals of this study were to identify genetic variants of hMATE1 and to determine their effects on hMATE1 transport function. We identified four synonymous and six nonsynonymous, coding region variants in DNA samples from 272 individuals (68 Caucasians, 68 African Americans, 68 Asian Americans and 68 Mexican Americans). The overall prevalence of hMATE1 nonsynonymous variants was relatively low with three singleton variants and three variants having allele frequencies ⩾2% in a specific ethnic group. The nonsynonymous hMATE1 variants were constructed and stably transfected into HEK-293 cells. Uptake studies using four known hMATE1 substrates (paraquat, metformin, tetraethylammonium and oxaliplatin) were performed in cells transfected with hMATE1 reference or variants. We found that two singleton variants, G64D and V480M, produced a complete loss of function for all four tested substrates whereas three polymorphic variants (allele frequencies ⩾2%), L125F, V338I and C497S, significantly altered the transport function in a substrate-dependent manner. Confocal microscopy studies were consistent with functional studies suggesting that the altered function of the variants was due to altered localization to the plasma membrane. These data suggest that nonsynonymous variants in hMATE1 may alter drug disposition and ultimately affect clinical drug response.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Abbreviations
- hMATE1:
-
human MATE1
- MATE:
-
multidrug and toxic compound extrusion
- OCT1:
-
organic cation transporter 1
- OCT2:
-
organic cation transporter 2
- SLC:
-
solute carrier superfamily
- SNP:
-
single nucleotide polymorphism
- TEA:
-
tetraethylammonium
References
Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y . A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005; 102: 17923–17928.
Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K . Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 2007; 74: 359–371.
Chen Y, Zhang S, Sorani M, Giacomini KM . Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 2007; 322: 695–700.
Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K . Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006; 319: 879–886.
Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006; 17: 2127–2135.
Smith AC, McGavran L, Robinson J, Waldstein G, Macfarlane J, Zonona J et al. Interstitial deletion of (17)(p11.2p11.2) in nine patients. Am J Med Genet 1986; 24: 393–414.
Bi W, Yan J, Stankiewicz P, Park SS, Walz K, Boerkoel CF et al. Genes in a refined Smith-Magenis syndrome critical deletion interval on chromosome 17p11.2 and the syntenic region of the mouse. Genome Res 2002; 12: 713–728.
Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–280.
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422–1431.
Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 2008; 83: 416–421.
Urban TJ, Sebro R, Hurowitz EH, Leabman MK, Badagnani I, Lagpacan LL et al. Functional genomics of membrane transporters in human populations. Genome Res 2006; 16: 223–230.
Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004; 65: 512–519.
Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003; 100: 5896–5901.
Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M et al. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol 2006; 290: F905–F912.
Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902–5907.
Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K . Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol 2007; 74: 477–487.
Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002; 12: 395–405.
Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006; 66: 8847–8857.
Acknowledgements
This work was supported by National Institutes of Health grants GM61390 and GM74929, and a grant from NEDO, Tokyo. YC was supported by National Research Service Award T32 GM07546 from the National Institutes of Health. We acknowledge James E Shima for his helpful advice on this paper. We also thank Alexandra G Ianculescu for her technical support on GFP images.
Author information
Authors and Affiliations
Corresponding author
Additional information
Duality of interest
None declared.
Rights and permissions
About this article
Cite this article
Chen, Y., Teranishi, K., Li, S. et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 9, 127–136 (2009). https://doi.org/10.1038/tpj.2008.19
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2008.19
Keywords
This article is cited by
-
Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis
Drugs (2019)
-
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients
Chinese Journal of Cancer (2016)
-
MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
Blood Cancer Journal (2016)
-
Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine
Archives of Toxicology (2016)
-
Role of solute carriers in response to anticancer drugs
Molecular and Cellular Therapies (2014)